-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-517991-39-00
5
2025-07-22
Asthma
-
2024-519015-34-00
1
2025-06-30
Systemic Lupus Erythematosus
-
2024-518360-13-00
1
2025-06-18
HER2-positive metastatic breast cancer
-
2024-513112-99-00
5
2025-06-13
Active Psoriatic Arthritis Stratified by Prior Biologic Use
-
2023-505218-68-00
4
2025-06-12
Moderate-Severe Atopic Dermatitis
-
2024-515526-89-00
4
2025-05-16
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2024-516009-22-00
5
2025-04-30
myelodysplastic neoplasms/syndromes (MDS)
-
2024-515279-37-00
5
2025-04-17
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
-
2024-516791-15-00
4
2025-04-08
Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
-
2024-519239-40-01
3
2025-04-07
Glioblastom
-
2023-508076-11-00
5
2025-04-01
Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan w
-
2024-515861-33-00
4
2025-03-25
Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, an
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2024-511037-35-00
4
2025-01-31
Cyclosporine A is a well known medication and is used to prevent rejec
-
2023-505897-13-00
5
2024-12-02
Papulopustular Rosacea
-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2024-510807-13-00
10
2024-09-12
ulcerative colitis
-
2023-503705-10-00
6
2024-08-19
Dementia in Pick disease
-
2023-507654-33-00
9
2024-08-12
Refractory systemic lupus erythematosus (SLE)
-
2023-504962-52-00
5
2024-07-10
Triple negative breast cancer.
-
2023-509892-17-00
10
2024-07-09
Generalized myasthenia gravis
-
2023-504552-10-01
5
2024-05-14
Papulopustular acne